green checkmark Google Screened
  • Contact Us Today

    • This field is for validation purposes and should be left unchanged.
  • Drug Safety Alert – Xarelto

    Philadelphia Products Liability Lawyers fight hard to protect those injured by dangerous products. Galfand Berger is investigating potential lawsuits involving the blood thinner Xarelto.

    Xarelto patients have experienced a number of potentially deadly bleeding-related complications, including:

    • Cerebral (Brain) Bleeding
    • Gastrointestinal Hemorrhaging
    • Hemorrhagic Stroke
    • Wrongful Death due to Uncontrollable Internal Bleeding

    Xarelto, manufactured by Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has been widely prescribed to prevent stroke and blood clots in patients suffering from atrial fibrillation (arrhythmia of the heart), deep vein thrombosis (blood clots deep within the body), and pulmonary embolism (blood clots in the lungs), or to patients who have recently underwent a knee or hip replacement surgery.

    Since its appearance on the market, Xarelto has attained blockbuster status. In 2013, the drug racked up global sales of $1.3 billion.

    Like all blood thinners, this drug can cause serious internal hemorrhaging in some patients. However, Xarelto bleeding is difficult to stop, as there is no known reversal agent for this occurrence. Warfarin bleeding, by contrast, can be staunched rather quickly via the administration of vitamin K.

    In September 2013, a German media outlet reported a sharp spike in the number of serious medical incidents associated with Xarelto. The article noted that during the first 8 months of that year, Germany’s Federal Institute for Drugs and Medical Devices had received 958 reports of complications where the medication was the suspected cause, including 72 cases of death. By contrast, the blood thinner was implicated in just 750 adverse event reports, including 58 deaths, in all of 2012.

    According to the Institute for Safe Medicine Practices’ May 2014 QuarterWatch report, the U.S. Food & Drug Administration (FDA) received 680 reports of serious complications during the first quarter of 2013 that were related to Xarelto.  For the first time since its U.S. launch, the drug outpaced Pradaxa in number of adverse event reports.


    If you, a family member or friend have taken Xarelto and suffered a serious bleed or stroke, please contact the Philadelphia products liability lawyers at Galfand Berger, LLP at 1-800-222-8792 or contact us online for a free, no-obligation consultation.